HUTCHMED announces that sovalfenib has received US FDA Orphan Drug Designation for Primary Immune Thrombocytopenia -. Company announcement - FT.com.
🇺🇸 USA · Map
HUTCHMED announces that sovalfenib has received US FDA Orphan Drug Designation for Primary Immune Thrombocytopenia -. Company announcement - FT.com.
Want to see every report in real time?
Hundreds of sources worldwide, translated into your language, with alerts for what matters to you.
Sign up free Already have an account? Log in